Shengshi Taikang Named to the "2021 Most Influential Companies in Healthcare" List

Last night, the "2021 China Healthcare and Greater Health Industry Investment & Financing Honor List" was unveiled online, and Shengshi Taikang was successfully selected. "The Top 50 List of Most Influential Healthcare Companies of 2021." Last year, Shengshi Taikang achieved a series of remarkable milestones in the fields of diabetes, rare diseases, and cancer treatment, with significant progress made across all stages—from research and development to clinical trials and ultimately product launches.

"The Annual Healthcare and Greater Health Industry Investment & Financing Honor List" has been jointly launched for the fourth consecutive year by CHC Healthcare Consulting and CITIC Securities. ， As an authoritative ranking in the healthcare sector from a third-party perspective, this list is compiled based on a comprehensive analysis of the current state of investment and financing trends in the medical industry. It evaluates institutions across multiple dimensions—including their level of activity, number of investment projects, standout success stories, investment returns, total assets under management, as well as corporate fundraising and growth prospects—while adhering to principles of fairness and impartiality. A total of 17 awards were selected, spanning four categories: investment firms, investors, enterprises, and publicly listed companies.

Shengshi Taikang has been shortlisted for this year’s Top 50 Most Influential Companies list, truly reflecting its remarkable growth journey over the past year. In the field of blood sugar-lowering drugs, the company’s innovative new drug, Starglitin phosphate, entered clinical trials last year. III The critical phase of the project is now being successfully concluded, with the potential to fill the domestic gap in original DPP-4 inhibitors. The investigational FGFR/VEGFR dual-target inhibitor CGT-6321 was approved for clinical trials last year and is currently undergoing a Phase 1 clinical trial in patients with advanced solid tumors. The drug holds promise as a potential "first-in-class" therapy. Additionally, China's first domestically developed generic version of teriflunomide tablets—a treatment for the rare disease multiple sclerosis—has been approved and is now available, offering patients a new, more accessible treatment option.

Founded in 2010 in Suzhou Industrial Park, Shengshi Taikang boasts a core team with decades of international experience spanning the entire lifecycle of pharmaceuticals. The company is dedicated to the research, development, and industrialization of innovative small-molecule drugs aimed at delivering breakthrough therapies. Leveraging an integrated drug R&D technology platform and a diversified business perspective, Shengshi Taikang has built a robust pipeline of cutting-edge drug candidates, targeting key therapeutic areas such as diabetes management, cancer treatment, and rare diseases. Looking ahead, the company will remain steadfastly focused on addressing unmet clinical needs—both in China and globally. Developing innovative drugs that are highly accessible and offer superior therapeutic efficacy to benefit patients worldwide.